The international team behind the new research studied 109,504 people who were just starting urate-lowering treatment, with allopurinol.
The data showed that those whose uric acid levels dropped below 6 mg/dL in the first 12 months also had a 9 percent lower risk of a significant cardiovascular event over the 5-year study period, compared with those who missed the target.
Why this should be true is as yet unknown.
